Caris Life Sciences Inc(CAI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 17 at 6:09 PM ET (Korea 9/18 07:09)
Full metrics table
| Index | - | P/E | 83.05 | EPS (ttm) | 0.37 | Insider Own | 55.3% | Shs Outstand | 282.6M | Perf Week | 28.62% |
| Market Cap | 8.74B | Forward P/E | 87.33 | EPS next Y | 192.53% | Insider Trans | -0.32% | Shs Float | 126.3M | Perf Month | 47.45% |
| Enterprise Value | 8.40B | PEG | - | EPS next Q | 0.03 | Inst Own | 49.26% | Short Float | 10.83% | Perf Quarter | 73.12% |
| Income | 0.11B | P/S | 8.83 | EPS this Y | 129.72% | Inst Trans | -1.38% | Short Ratio | 3.06 | Perf Half Y | 67.41% |
| Sales | 0.99B | P/B | 14.77 | EPS next 5Y | - | ROA | 9.62% | Short Interest | 13.68M | Perf YTD | 14.6% |
| Book/sh | 2.09 | P/C | 11.02 | EPS past 3/5Y | -7.57% - | ROE | 20.13% | 52W High | -10.49% ($34.54) | Perf Year | -7.78% |
| Cash/sh | 2.81 | P/FCF | 75.16 | Sales past 3/5Y | 62.87% - | ROIC | 10.13% | 52W Low | 117.9% ($14.19) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 48.25 | EPS Y/Y TTM | 113.1% | Gross Margin | 69.66% | Volatility(W/M) | 6.6% 5.85% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 8.49 | Sales Y/Y TTM | 85.37% | Oper. Margin | 15.49% | ATR (14) | 1.52 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.88 | EPS Q/Q | 99.88% | Profit Margin | 10.62% | RSI (14) | 76.25 | Recom | 1.64 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.53 | Sales Q/Q | 45.38% | SMA20 | 18.88% ($26.01) | Beta | 0.86 | Target Price | $27.38 |
| Payout | - | Debt/Eq | 0.76 | Earnings | 2026/8/5 | SMA50 | 45.08% ($21.31) | Rel Volume | 1.68 | Prev Close | $28.21 |
| Employees | 1846 | LT Debt/Eq | 0.75 | EPS/Sales Surpr. | -100% 10.75% | SMA200 | 47.12% ($21.02) | Avg Volume(3M) | 4.47M | Price | $30.92 |
| IPO | 2025/6/18 | Option/Short | Yes/Yes | Trades | 42897 | Volume | 7,526,601 | Change | 9.61% |
Company
CAI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 An AI-powered diagnostics company specializing in cancer molecular diagnostics and precision medicine. It supports personalized treatment for cancer patients through whole-genome and whole-transcriptome sequencing that analyzes tumor tissue and blood, and is rapidly growing in the field of precision oncology based on its extensive molecular database. Its core business is molecular profiling services.
Over the past 1 year, on the higher side
10% below its 1-year high.
CAI makes money exceptionally well
15.49% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +129.7% this year.
Tap to view numbers
But it is not cheap
Trading at 83.0 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 49.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IDNA 0.02%
GNOM 0.02%
FMED 0.02%
LYTE 0.01%
EKG 0.01%It ranks #4 in the industry
Based on market cap of $9B.
CAI $9B PER 83.0
VRTX $131B PER 30.0
REGN $81B PER 19.5
MRNA $63B PER -
FAQ
What kind of company is CAI?
CAI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CAI?
The market cap of CAI is approximately $8.7B, ranking 1,020 within its sector.
What is the P/E ratio of CAI?
CAI has a P/E ratio of approximately 83.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for CAI?
CAI has recorded a 52-week high of $34.54 and a low of $14.19.
